CVI Holdings’s Starling Oncology STLN Stock Holding History

CVI Holdings’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-200,000	Closed	-$1.95M	–	957
2021 Q4	$1.95M	Buy	+200,000	New	+$1.78M	0.13%	263

Other funds holding STLN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

PGM

Parian Global Management Pound Ridge, New York $30.8M AUM 51.25% 1-Year Est. Return

Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return

SCM

Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

CVI Holdings's STLN Position: Q1 2022 in Review

CVI Holdings sold out of Starling Oncology (STLN) in Q1 2022, closing a stake of 200,000 shares — an estimated $1.95M sold.

CVI Holdings first reported a position in STLN in Q4 2021 and held it in 1 quarter. The position peaked at $1.95M in Q4 2021. 29 funds tracked by Wall St. Rank hold STLN as of Q1 2022.

CVI Holdings reported no remaining Starling Oncology position as of Q1 2022 after selling out during the quarter.
CVI Holdings sold 200,000 Starling Oncology shares in Q1 2022, an estimated $1.95M.
CVI Holdings first reported a position in Starling Oncology in Q4 2021 and held it in 1 quarter.
CVI Holdings's Starling Oncology position peaked at $1.95M in Q4 2021.
29 funds tracked by Wall St. Rank held Starling Oncology as of Q1 2022.

Based on CVI Holdings's 13F filing for Q1 2022, filed 16 May 2022.